How many LIXT restricted share units did the CEO acquire in this Form 4?

The CEO acquired 350,000 restricted share units in this Form 4 filing. These units were granted as a stock award, with each RSU representing a contingent right to receive one share of Lixte common stock upon vesting and subject to service conditions.

Lixte (LIXT) CEO awarded 350,000 RSUs, total holdings now 700,000

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Lixte Biotechnology Holdings CEO Geordan Garrett Pursglove reported an acquisition of equity-based compensation through restricted share units. On July 1, 2026, he received 350,000 RSUs at a stated price of $0.00 per share as a grant or award.

Each RSU represents a right to receive one share of common stock upon vesting, tied to continued service and performance conditions that have already been satisfied. After this award, his reported holdings total 700,000 RSUs, including the 350,000 newly awarded RSUs and 350,000 RSUs that have fully vested.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Pursglove Geordan Garrett

Role CEO and Chairman of the Board

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	350,000	$0.00	--

Holdings After Transaction: Common Stock — 700,000 shares (Direct, null)

Footnotes (1)

The reported transaction involved the Reporting Person's receipt of 350,000 restricted share units ("RSUs"). The RSUs were granted pursuant to the applicable RSU agreement and the Lixte Biotechnology Holdings, Inc. 2020 Stock Incentive Plan. Each RSU represents a contingent right to receive one share of common stock upon vesting, subject to continued service. The 350,000 RSUs vested upon the achievement of the performance conditions set forth in the Reporting Person's RSU agreement, which have been satisfied. The total reported in Column 5 includes (i) the 350,000 newly awarded RSUs, and (ii) 350,000 RSUs, all of which have vested.

Key Figures

RSUs granted: 350,000 RSUs Total RSUs after transaction: 700,000 RSUs Grant price per share: $0.00 per share +1 more

4 metrics

RSUs granted 350,000 RSUs Grant/award acquisition on July 1, 2026

Total RSUs after transaction 700,000 RSUs Reported holdings in Column 5 after grant

Grant price per share $0.00 per share Stated transaction price for RSU award

Transaction code Code A Grant, award, or other acquisition of common stock

Key Terms

restricted share units ("RSUs"), 2020 Stock Incentive Plan, performance conditions

3 terms

2020 Stock Incentive Plan financial

"The RSUs were granted pursuant to the applicable RSU agreement and the Lixte Biotechnology Holdings, Inc. 2020 Stock Incentive Plan."

performance conditions financial

"The 350,000 RSUs vested upon the achievement of the performance conditions set forth in the Reporting Person's RSU agreement, which have been satisfied."

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 07/02/2026 - 04:14 PM Accepted by SEC EDGAR 07/02/2026 - 04:13 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Pursglove Geordan Garrett

(Last)

(First)

(Middle)

433 PLAZA REAL, SUITE 275

(Street)

BOCA RATON

FLORIDA

33432

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
LIXTE BIOTECHNOLOGY HOLDINGS, INC. [ LIXT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	CEO and Chairman of the Board

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	07/01/2026		A		350,000⁽¹⁾	A	$0	700,000⁽²⁾	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. The reported transaction involved the Reporting Person's receipt of 350,000 restricted share units ("RSUs"). The RSUs were granted pursuant to the applicable RSU agreement and the Lixte Biotechnology Holdings, Inc. 2020 Stock Incentive Plan. Each RSU represents a contingent right to receive one share of common stock upon vesting, subject to continued service. The 350,000 RSUs vested upon the achievement of the performance conditions set forth in the Reporting Person's RSU agreement, which have been satisfied.

2. The total reported in Column 5 includes (i) the 350,000 newly awarded RSUs, and (ii) 350,000 RSUs, all of which have vested.

	/s/ Geordan Pursglove	07/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did LIXT CEO Geordan Garrett Pursglove report?

LIXT CEO Geordan Garrett Pursglove reported receiving 350,000 restricted share units as equity compensation. These RSUs were granted at a stated price of $0.00 per share and increase his total reported RSU holdings to 700,000 units tied to company common stock.

What is the total LIXT equity position reported after this RSU grant?

After this grant, the CEO’s total reported position is 700,000 restricted share units. This figure combines 350,000 newly awarded RSUs with 350,000 RSUs that have already vested, as disclosed in the footnotes to the Form 4 transaction information.

Were performance conditions tied to the new LIXT RSU award for the CEO?

Yes, the 350,000 newly awarded RSUs vested upon achievement of specified performance conditions. The Form 4 footnotes state these conditions, set out in the CEO’s RSU agreement, have been satisfied, and vesting also remains subject to the CEO’s continued service with the company.

Under which plan were the LIXT CEO’s RSUs granted?

The CEO’s 350,000 RSUs were granted under the Lixte Biotechnology Holdings, Inc. 2020 Stock Incentive Plan. The grant was made pursuant to the applicable RSU agreement, which defines vesting terms, performance conditions, and the link between each RSU and one share of common stock.

Does the LIXT Form 4 indicate a market purchase or sale of shares?

No, the Form 4 reflects a grant or award of 350,000 RSUs, not an open-market trade. The transaction code is “A” for acquisition, with a $0.00 per-share price, indicating compensation-related equity rather than a purchase or sale in the public market.